Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
660
datasets available to search
ShareScore release 0.9.0
Dataset results
660 results for “antitumor”
Figure 1 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 1 In vivo experiment: groups of EMT-6/P and EMT-6/V inoculated mice, Treatment approaches were: baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), and vincristine (2 mg/kg/every other day). The same concentrations were used in the combination treatment and triple therapy.
Figure 19 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 19 ALT serum level (U/L) in different treatment groups. Concentrations used baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group in EMT-6/P and EMT-6/V. Including the statistical correlations between groups.
Figure 14 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 14 The volume change (mm3) for treatment groups in vivo for EMT-6/P and EMT-6/V. Only statistically significant associations are shown. Positive control (PBS and tween 20%), baicalin 75 mg/kg/day, EGCG: 50 mg/kg/day, baicalin and EGCG combination 75 and 50 mg/kg/day respectively, vincristine 2mg/kg/every other day, and same doses were used in the triple therapy.
Figure 9 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 9 Tumor sizes of EMT-6/P after dissection at day 10 in all groups compared to each other, n = 7 except for the last two groups n = 6.
Figure 8 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 8 Folds increase in caspase-3 activity and apoptosis induction, concentrations used were: baicalin 175 µM, EGCG 125 µM, baicalin, and EGCG 140 and 100 µM respectively, vincristine 643 µg/ml and positive control treated with MEM in EMT-6/V.
Figure 3 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 3 Anti-proliferative effect of EGCG in single treatment against EMT-6/P and EMT-6/V cell lines.
Figure 23 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 23 Creatinine serum levels (mg/dl) in different treatment groups. Concentrations used baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group in EMT-6/P and EMT-6/V. Including the statistical correlations between groups.
Figure 4 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 4 The sensitivity of EMT-6/P and EMT-6/V cell lines to vincristine was measured by testing decreasing concentrations of vincristine using the anti-proliferative assay (MTT).
Figure 5 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 5 Anti-proliferation effect of EGCG and baicalin in combination treatment against EMT-6/P different doses of EGCG with a fixed dose of baicalin (114 µM).
Figure 21 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 21 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on average creatinine measured by (mg/dl) in EMT-6/P.
Figure 2 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 2 Anti-proliferative effect of baicalin in single treatment against EMT-6/P and EMT-6/V cell lines.
Figure 12 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 12 A plot of change in average tumor size (mm³) vs. time in days of treatment in EMT-6/V cell line.
Figure 20 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 20 AST serum level (U/L) in different treatment groups. Concentrations used baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group in EMT-6/P and EMT-6/V. Including the statistical correlations between groups.
Blockade of LAG3 and PD1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
<p>This is the data necessary to reproduce the figures from "<em>Blockade of LAG3 and PD1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity</em>" by Cillo et al.</p>
Fig. 3 in Abietane diterpenes from the twigs and leaves of Cephalotaxus oliveri Mast. with antitumor activity
Fig. 3. Key ROESY correlations of 1–4, 16, 20, and 21.
Fig. 1 in Abietane diterpenes from the twigs and leaves of Cephalotaxus oliveri Mast. with antitumor activity
Fig. 1. The structures of abietane diterpenes 1–21 from C. oliveri.
Fig. 4. Experimental and B3 in Abietane diterpenes from the twigs and leaves of Cephalotaxus oliveri Mast. with antitumor activity
Fig. 4. Experimental and B3LYP/6-31G (d,p)-calculated ECD spectra of 1–4, 16, 20, and 21.
Fig. 33. Dehydrobruceine B in Quassinoids: Phytochemistry and antitumor prospect
Fig. 33. Dehydrobruceine B triggers apoptosis in A549 and NCI–H292 cells via mitochondrial pathway.
Fig. 23 in Quassinoids: Phytochemistry and antitumor prospect
Fig. 23. The main skeleton and possible biogenetic pathway of C19-quassinoids.
Fig. 30 in Quassinoids: Phytochemistry and antitumor prospect
Fig. 30. SAR studies of class D quassinoids against human cancer cells.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.